Our data support the potential for combining BETi with anti-PD1 to rescue anti-PD1 refractoriness in AML and describe a unique role of BRD4 and BRD4 targeting therapies in regulating T cell differentiation. This evidence concerns the gene BRD4 and acute myeloid leukemia.